Muñoz-Ramírez H, Khosla M C, Bumpus F M, Khairallah P A
Eur J Pharmacol. 1975 Mar;31(1):122-35. doi: 10.1016/0014-2999(75)90085-0.
In ganglion blocked vagotomized rats, several 1,8-substituted angiotensin II analogs (250 ng/kg/min, i.v.) antagonized the pressor effect of angiotensin II. Dose ratios measured at the ED20 levels were: [Sar1,Ile8]-28; [Gac1,Ile8]- 19;[MeAla1,Ile8i1- 16;[MeIle1,Ile8]- 10;[sar1,Ala8]- 9;[me2Gly1,Ile8]- 4. Elimination of aspajtic acid in position 1 of [Ile8]-angiotensin II significantly reduced the antagonistic potency of the analog. No antagonistic effect was observed with [Phe4,Ile8] and [Ala4,Ile8]-angiotensin II even when infused at 6 mug/kg/min. During infusion, a partial rise in blood pressure was observed with all the above 1,8-substituted angiotensin II analogs. Phentolamine (100 mug/rat) injected 30 min after the start of the analog infusion reduced and sometimes abolished the pressor effect. However, phenoxybenzamine )Pbz, 2 mg/kg) injected 30 min prior to the analog infusion diminished but did not completely abolish the initial pressor effect. In adrenalectomized rats, the pressor effect was reduced by approximately 50 percent and disappeared completely 15-30 min after start of the infusion. Under these conditions, dose ratios of [Sar1,Ile8]-,[MeAla1,Ile8]- and [Gac1,Ile8]-angiotensin II were significantly reduced. Noradrenaline, 83 ng/kg/min. increased the ED20 value of angiotensin II(ratio 1.79) in normal rats but did not do so in adrenalectomized rats. In these rats no regular correlation was found between the angiotensin II ED20 values and initial blood pressure. These data indicate that under the present experimental conditions, the low pressor effect observed with these angiotensin II antagonists appears to be due to both adrenal catecholamine release and a direct vasoconstrictor effect. Variations in antagonistic activity of angiotensin II analogs, apart from changes introduced in the molecule, may be the manifestation of a complex interaction between angiotensin II, its antagonists, and the sympathoadrenal system.
在神经节阻断并切断迷走神经的大鼠中,几种1,8-取代的血管紧张素II类似物(静脉注射,250 ng/kg/min)可拮抗血管紧张素II的升压作用。在ED20水平测得的剂量比为:[Sar1,Ile8]-28;[Gac1,Ile8]-19;[MeAla1,Ile8]-16;[MeIle1,Ile8]-10;[sar1,Ala8]-9;[me2Gly1,Ile8]-4。[Ile8]-血管紧张素II第1位天冬氨酸的消除显著降低了该类似物的拮抗效力。[Phe4,Ile8]和[Ala4,Ile8]-血管紧张素II即使以6 μg/kg/min的速度输注也未观察到拮抗作用。在输注过程中,上述所有1,8-取代的血管紧张素II类似物均观察到血压有部分升高。在类似物输注开始30分钟后注射酚妥拉明(100 μg/只大鼠)可降低并有时消除升压作用。然而,在类似物输注前30分钟注射酚苄明(Pbz,2 mg/kg)可减弱但并未完全消除初始升压作用。在肾上腺切除的大鼠中,升压作用降低了约50%,并在输注开始后15 - 30分钟完全消失。在这些条件下,[Sar1,Ile8]-、[MeAla1,Ile8]-和[Gac1,Ile8]-血管紧张素II的剂量比显著降低。去甲肾上腺素,83 ng/kg/min,可增加正常大鼠中血管紧张素II的ED20值(比值1.79),但在肾上腺切除的大鼠中则无此作用。在这些大鼠中,未发现血管紧张素II的ED20值与初始血压之间有规律的相关性。这些数据表明,在当前实验条件下,用这些血管紧张素II拮抗剂观察到的低升压作用似乎是由于肾上腺儿茶酚胺释放和直接血管收缩作用共同所致。除分子中引入的变化外,血管紧张素II类似物拮抗活性的变化可能是血管紧张素II、其拮抗剂和交感肾上腺系统之间复杂相互作用的表现。